ZELANCT06897839
Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 11 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 50 → 56 locations
- Study description expanded, about 40 words
- Notable Eligibility criteria expanded, about 11 words
- Study sites: 50 to 49
- Minor Site details revised at 11 of 50 sitesv10
- Minor Site details revised at 3 of 50 sitesv9
- Minor Site details revised at 4 of 50 sitesv8
- Minor Trial sites expanded: 20 → 50 locationsv7
- Minor Study sites: 18 to 20v6
- Notable Trial status: Active, Not Recruiting to Recruiting
- Primary completion date: Dec 31, 2027 to Mar 31, 2028
- Study completion date: Feb 28, 2030 to Apr 30, 2030
- Site details revised at 18 of 18 sites
Notable Phase: Phase 3 to Phase 2/3v3 Show 8 more changesShow less
- Eligibility criteria revised
- Enrollment target: 316 to 366
- Study sites: 15 to 18
- Primary completion date: Aug 30, 2027 to Dec 31, 2027
- Study completion date: Jul 30, 2029 to Feb 28, 2030
- Secondary endpoints: 15 to 23
- Study arms: 2 to 3
- Study title expanded, about 2 words
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 15 of 15 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (19)
Show 14 moreShow less
Arms and interventions
In addition to the preterm neonate standard of care, the subjects randomized to this treatment arm will receive up to 7 administrations of zelpultide alfa at 4 mg/kg (birth weight) in 24 h intervals while the subjects are still intubated.
In addition to the preterm neonate standard of care, approximately 1 mL of air drawn into a dosing syringe will be administered up to 7 times to neonate subjects randomized to the control (placebo) arm, following the same means and intervals as in the treatment arm.
In addition to the preterm neonate standard of care, the subjects randomized to this treatment arm will receive up to 7 administrations of zelpultide alfa at 6 mg/kg (birth weight) in 24 h intervals while the subjects are still intubated.
Other: Air-sham
Drugs: Zelpultide alfa
Sites
56 sites in 10 countries
Spain 13, France 8, Germany 6, Italy 6, Poland 6, Belgium 5, Israel 5, Argentina 4, Czechia 2, Portugal 1